243 related articles for article (PubMed ID: 29026313)
1. Pneumonitis and pneumonitis-related death in cancer patients treated with programmed cell death-1 inhibitors: a systematic review and meta-analysis.
Cui PF; Ma JX; Wang FX; Zhang J; Tao HT; Hu Y
Ther Clin Risk Manag; 2017; 13():1259-1271. PubMed ID: 29026313
[TBL] [Abstract][Full Text] [Related]
2. Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis.
Su Q; Zhu EC; Wu JB; Li T; Hou YL; Wang DY; Gao ZH
Front Immunol; 2019; 10():108. PubMed ID: 30778352
[No Abstract] [Full Text] [Related]
3. Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis.
Nishino M; Giobbie-Hurder A; Hatabu H; Ramaiya NH; Hodi FS
JAMA Oncol; 2016 Dec; 2(12):1607-1616. PubMed ID: 27540850
[TBL] [Abstract][Full Text] [Related]
4. Risk of immune-related pneumonitis for PD1/PD-L1 inhibitors: Systematic review and network meta-analysis.
Huang Y; Fan H; Li N; Du J
Cancer Med; 2019 May; 8(5):2664-2674. PubMed ID: 30950194
[TBL] [Abstract][Full Text] [Related]
5. Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.
Khunger M; Rakshit S; Pasupuleti V; Hernandez AV; Mazzone P; Stevenson J; Pennell NA; Velcheti V
Chest; 2017 Aug; 152(2):271-281. PubMed ID: 28499515
[TBL] [Abstract][Full Text] [Related]
6. Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis.
Abdel-Rahman O; Fouad M
Ther Adv Respir Dis; 2016 Jun; 10(3):183-93. PubMed ID: 26944362
[TBL] [Abstract][Full Text] [Related]
7. Treatment-related Death in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Abdel-Rahman O; Helbling D; Schmidt J; Petrausch U; Giryes A; Mehrabi A; Schöb O; Mannhart M; Oweira H
Clin Oncol (R Coll Radiol); 2017 Apr; 29(4):218-230. PubMed ID: 27894673
[TBL] [Abstract][Full Text] [Related]
8. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
Nishijima TF; Shachar SS; Nyrop KA; Muss HB
Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115
[TBL] [Abstract][Full Text] [Related]
9. Risk of Immune-Related Pneumonitis with PD-1/PD-L1 Inhibitors in Different Cancer Types and Treatment Regimens: A Systematic Review and Meta-Analysis of 22 Randomized Controlled Trials.
Han L; Li G; Li H; Zhao L
Chemotherapy; 2023; 68(1):1-15. PubMed ID: 35249037
[TBL] [Abstract][Full Text] [Related]
10. [Immune-related pneumonitis caused by programmed death-1 inhibitor Pembrolizumab: a case report and literature review].
Chen YL; Zhao J; Jia R; Wang HY; Zheng J; Bai CQ; Wang MZ; Xu JM
Zhonghua Jie He He Hu Xi Za Zhi; 2017 Oct; 40(10):736-743. PubMed ID: 29050127
[No Abstract] [Full Text] [Related]
11. Risk of Pneumonitis Associated with Programmed Cell Death 1 Inhibitors in Cancer Patients: A Meta-analysis.
Zhang S; Liang F; Zhu J; Chen Q
Mol Cancer Ther; 2017 Aug; 16(8):1588-1595. PubMed ID: 28446641
[TBL] [Abstract][Full Text] [Related]
12. The risk of immune-related endocrine disorders associated with anti-PD-1 inhibitors therapy for solid tumors: A systematic review and meta-analysis.
Su Q; Zhang XC; Wang DY; Zhang HR; Zhu C; Hou YL; Liu JL; Gao ZH
Int Immunopharmacol; 2018 Jun; 59():328-338. PubMed ID: 29679857
[TBL] [Abstract][Full Text] [Related]
13. The Relative Risk and Incidence of Immune Checkpoint Inhibitors Related Pneumonitis in Patients With Advanced Cancer: A Meta-Analysis.
Ma K; Lu Y; Jiang S; Tang J; Li X; Zhang Y
Front Pharmacol; 2018; 9():1430. PubMed ID: 30618738
[No Abstract] [Full Text] [Related]
14. Treatment-associated Fatigue in Cancer Patients Treated with Immune Checkpoint Inhibitors; a Systematic Review and Meta-analysis.
Abdel-Rahman O; Helbling D; Schmidt J; Petrausch U; Giryes A; Mehrabi A; Schöb O; Mannhart M; Zidan A; Oweira H
Clin Oncol (R Coll Radiol); 2016 Oct; 28(10):e127-38. PubMed ID: 27339403
[TBL] [Abstract][Full Text] [Related]
15. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
[TBL] [Abstract][Full Text] [Related]
16. Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis of published data.
Wang W; Lie P; Guo M; He J
Int J Cancer; 2017 Sep; 141(5):1018-1028. PubMed ID: 28263392
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis.
Hu YB; Zhang Q; Li HJ; Michot JM; Liu HB; Zhan P; Lv TF; Song Y;
Transl Lung Cancer Res; 2017 Dec; 6(Suppl 1):S8-S20. PubMed ID: 29299404
[TBL] [Abstract][Full Text] [Related]
18. Risk of hematologic toxicities with programmed cell death-1 inhibitors in cancer patients: a meta-analysis of current studies.
Sui JD; Wang Y; Wan Y; Wu YZ
Drug Des Devel Ther; 2018; 12():1645-1657. PubMed ID: 29922039
[TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy of PD-1/PD-L1 Inhibitors in Treatment-Naive and Chemotherapy-Refractory Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Khunger M; Jain P; Rakshit S; Pasupuleti V; Hernandez AV; Stevenson J; Pennell NA; Velcheti V
Clin Lung Cancer; 2018 May; 19(3):e335-e348. PubMed ID: 29433902
[TBL] [Abstract][Full Text] [Related]
20. The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review.
Chai QQ; Du JY; Zhu J; Wu B
Front Pharmacol; 2019; 10():1260. PubMed ID: 31708783
[No Abstract] [Full Text] [Related]
[Next] [New Search]
